Innovative ETFs ChannelModerna’s Omicron Booster Strategy Lifts Biotechnology ETFsBy Max ChenNovember 29, 2021
Innovative ETFs ChannelPfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFsBy Max ChenNovember 5, 2021
Innovative ETFs ChannelModerna Vaccine Is Granted Authorization in AustraliaBy Max ChenAugust 9, 2021
Innovative ETFs ChannelA Biotech ETF to Track Nasdaq’s Industry-Setting BenchmarkBy Max ChenJune 30, 2021
Model Portfolio ChannelThe BioRevolution: An ETF That Taps Into Nearly EverythingBy Max ChenJune 21, 2021
Multi-Factor ChannelInvesting for Tomorrow, Today: Exploring the Future of Health CareBy Max ChenApril 28, 2021
Innovative ETFs ChannelGreater Regulatory Scrutiny Could Weigh on Biotech ETFsBy Max ChenMarch 24, 2021
Beyond Basic Beta ChannelBiotech Shined with Vaccines. It Can Do It Again with ‘BBH’By Ben HernandezMarch 3, 2021
Innovative ETFs ChannelIllumina Earnings, Forward Guidance Strengthen Biotech ETFsBy Max ChenFebruary 12, 2021
Innovative ETFs ChannelBiotechnology ETFs Soar on Biogen’s New Alzheimer’s DrugBy Max ChenJanuary 29, 2021
Leveraged & Inverse ChannelUp Over 100% in 2020 and 15% in 2021, ‘LABU’ Isn’t Holding BackBy Ben HernandezJanuary 12, 2021
Innovative ETFs ChannelConsider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021By Max ChenDecember 31, 2020
Thematic Investing ChannelGet On Board a Growing Biotech Industry With the GNOM ETFBy Ben HernandezDecember 23, 2020
